Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 15/20 | 0.68 |
| ▸ | HDAC1 | Q13547 | 14/20 | 0.68 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.68 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.61 |
| ▸ | NCOR2 | Q9Y618 | 3/20 | 0.61 |
| ▸ | PDE6C | P51160 | 2/20 | 0.60 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16003653 | 0.89 | PDE5A (0.77) | PDE5AHDAC6HDAC1PDE3AHDAC2 | |
| SCHEMBL17390135 | 0.89 | PDE5A (0.64) | PDE5AHDAC6HDAC1PDE3AHDAC2 | |
| SCHEMBL17390124 | 0.87 | PDE5A (0.75) | PDE5AHDAC6HDAC1PDE3AHDAC2 | |
| SCHEMBL17979324 | 0.86 | PDE5A (0.75) | PDE5AHDAC6HDAC1PDE3AHDAC2 | |
| SCHEMBL17390117 | 0.86 | PDE5A (0.70) | PDE5AHDAC6HDAC1PDE3AHDAC2 | |
| SCHEMBL18715295 | 0.86 | PDE5A (0.70) | PDE5AHDAC6HDAC1PDE3AHDAC2 | |
| SCHEMBL17980848 | 0.85 | PDE5A (0.76) | PDE5AHDAC6HDAC1PDE3AHDAC2 | |
| SCHEMBL17390153 | 0.85 | PDE5A (0.73) | PDE5AHDAC6HDAC1PDE3AHDAC2 | |
| SCHEMBL16003783 | 0.85 | PDE5A (0.89) | PDE5AHDAC6HDAC1PDE3AHDAC2 | |
| SCHEMBL16003753 | 0.85 | PDE5A (0.89) | PDE5AHDAC6HDAC1PDE3AHDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2961741-B1 | NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES | FUND PARA LA INVESTIG MEDICA APLICADA (ES) | 2017-04-05 | — | — | EP | disclosed |
| US-9573956-B2 | Compounds as dual inhibitors of phosphodiesterases and histone deacetylases | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2017-02-21 | — | — | US | disclosed |
| US-20160002246-A1 | NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2016-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002246-A1 | NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES | PDE1A, HDAC1, HDAC2 | PDE5A 24/4885HDAC6 12/4885HDAC1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.